• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Escitalopram not linked to improved outcomes in heart failure patients with depression

byJohn PrendergassandMichael Milligan
June 30, 2016
in Cardiology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Chronic systolic heart failure patients treated for 18 months with escitalopram, an SSRI, did not demonstrate significantly reduced all-cause mortality.

2. It was also shown that chronic heart failure patients treated with escitalopram did not demonstrate significant improvement in depression.

Evidence Rating Level: 1 (Excellent)

Study Rundown: According to the National Institutes of Health (NIH), depression is one of the most common mental disorders in the United States, affecting roughly 16 million adults, or 6.7% of the population over the age of 18. However, depression is not an isolated condition, nor one with a singular cause. For example, depression has been shown to be more common in patients with cardiovascular disease and its presence results in worse overall outcomes for these patients. Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat depression. Only 1 previous randomized controlled trial, lasting just 12 weeks, assessed the effects of SSRIs on patients with heart failure. This study, designed to follow patients for 12 months, was aimed at understanding the long term effects of SSRIs on heart failure.

The study found that in chronic systolic heart failure patients treated with long term (12 months) escitalopram, mortality and hospitalization rates were no different than those treated with a placebo. The study is strengthened by its double-blind, placebo-controlled design, and long follow-up period. However, being a primarily white population from Germany, the study population lacked both ethnic and geographic diversity, possibly limiting generalizability. The results of this trial, combined with those of prior studies, do not support the notion that escitalopram should be used to treat depression in patients with chronic systolic heart failure. Future studies could focus on determining if these results persist with other anti-depressants used in similar patient groups as well as sub-groups such as the elderly, African-Americans, and women.

Click to read the study in JAMA

Relevant Reading: Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF Trial

RELATED REPORTS

Islamic-based interventions may improve both depression and anxiety

Wellness Check: Spirituality

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

In-Depth [randomized clinical trial]: This study examined 372 patients with chronic systolic heart failure and depression from 16 tertiary medical centers in Germany. 185 were assigned to receive escitalopram and 187 to the placebo group. Primary outcomes of all-cause death or hospitalization occurred in 116 (63%) patients in the escitalopram group and 119 patients (64%) in the placebo group (HR 0.99; 95%CI 0.76 to 1.27, p = 0.92). Treatment adherence at study visit 3 was 86% but decreased to 73% by study visit 6. The proportion of patients discontinuing treatment after 6 and 12 weeks was 11% and 15% for the escitalopram group and 5% and 7% for the placebo group, respectively.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: depressionheart failure
Previous Post

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Next Post

PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma

RelatedReports

Children’s hospital visits for suicide ideation and attempts are increasing
Psychiatry

Islamic-based interventions may improve both depression and anxiety

June 22, 2022
Wellness

Wellness Check: Spirituality

June 21, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

June 9, 2022
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Psychiatry

Gratitude-focused writing may improve mental wellness during periods of chronic stress

May 24, 2022
Next Post
PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma

PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma

Amyloidogenic genetic variant not associated with increased mortality in blacks

2 Minute Medicine Rewind June 27, 2016

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Two vaccines protect against Zika virus infection in mice [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.